Newly released clinical trial data on the GLP-1 agonist drug Wegovy found that weight loss was sustained for up to four years ...

A Northwestern Medicine study shows that technology alone can't replace the human touch to produce meaningful weight loss in ...

Researchers are looking to see if GLP-1 receptor agonists, DPP4 inhibitors, and SGLT2 inhibitors have beneficial effects in ...

Company ended the quarter with $29.5 million in cashDETECT-trial recruitment completed; Company continues to expect the completion of the trial ...

Unregulated use of fentanyl and overdose deaths have increased dramatically in recent years, and this trend was made more ...

Losing 80 pounds with the help of medication has brought a lot of positives — but Allie Olivares wants others to know it ...

Semaglutide remains effective for weight loss at 4 years in people with preexisting cardiovascular disease and ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window One in eight U.S. adults have taken semaglutide ...

A new poll found that one in eight American adults had used a GLP-1 drug, with half of those people still taking the ...

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on NGNE stock, giving a Buy rating yesterday. Mani Foroohar has ...

The growing popularity of GLP-1 drugs opens up massive opportunities for biopharma companies, life sciences firms and ...

A poll from the health policy nonprofit KFF found that 1 in 8 adults say they’ve taken a GLP-1 agonist, the obesity and ...